Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


New drug delivery system could reduce daily diabetes shots to just three a year

Written by | 28 Nov 2023

Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro,… read more.

Simple automated tool prompts physicians to screen patients with diabetes for kidney disease

Written by | 6 Nov 2023

Investigators have implemented an automated health maintenance tool created by the National Kidney Foundation into electronic medical records to prompt primary care physicians to screen for chronic kidney… read more.

Tirzepatide equally effective for early-onset or later-onset type 2 diabetes

Written by | 10 Oct 2023

Tirzepatide. a once weekly GIP and GLP-1 receptor agonist, treats early-onset type 2 diabetes as effectively as it treats type 2 diabetes diagnosed later in life, researchers reported… read more.

Commonly prescribed antibiotic, antipsychotic and prokinetic drugs are associated with a higher risk of sudden cardiac arrest (SCA) in people with type 2 diabetes, study finds

Written by | 9 Oct 2023

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has identified a range of… read more.

Pharmacist-led intervention can improve medication adherence among Latinos with type 2 diabetes

Written by | 2 Oct 2023

UCLA-led research suggests that diabetes control can significantly improve for Latinos when a pharmacist implements an intervention that addresses these patients’ barriers to medication adherence. In this pharmacist-led… read more.

Making sense of GLP-1 agonists

Written by | 29 Sep 2023

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.

What does a consultant pharmacist in diabetes do?

Written by | 28 Sep 2023

The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes… read more.

Should GLP-1 agonists should be used earlier in type 2 diabetes?

Written by | 27 Sep 2023

In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications,… read more.

How GLP-1 agonists help in type 2 diabetes

Written by | 26 Sep 2023

GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.

Simple blood test may predict future heart, kidney risk for people with Type 2 diabetes

Written by | 24 Aug 2023

A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in… read more.

Once-weekly insulin icodec shows superiority to daily insulin glargine

Written by | 29 Jul 2023

Researchers report that patients have achieved significantly better glycemic control with once-weekly investigative insulin icodec than with with once-daily insulin glargine U100. The findings were reported on July… read more.

NHS England moves to restrict use of GLP-1 agonists

Written by | 10 Jul 2023

On 27th June 2023 NHS England issued a Medicine Supply Notification (MSN/2023/061) concerning GLP-1 receptor agonists (GLP-1 RAs) used for management of type 2 diabetes. This action has… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.